Binodenoson

Research use only, not for human use.

Binodenoson is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging.

Binodenoson is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging.(In Vitro):2-(cyclohexylmethylidenehydrazino)adenos (30-300 nM) decreases oxidative activity of tumor necrosis factor-α–primed FMLP-stimulated polymorphonuclear leukocytes in human whole blood and acts synergistically with Rolipram.(In Vivo):2-(cyclohexylmethylidenehydrazino)adenos (infused 0-0.9 μg/kg/h; adult Wistar rat; rat bacterial meningitis model), with or without rolipram (0-0.01 μg/kg/h), inhibits pleocytosis and reduces the lipopolysaccharide-induced increase in blood-brain barrier permeability (BBBP), indicative of decreased neutrophil-induced damage.

Binodenoson (MRE-0470) (30-300 nM) decreases oxidative activity of tumor necrosis factor-α–primed FMLP-stimulated polymorphonuclear leukocytes in human whole blood and acts synergistically with Rolipram.

Binodenoson (infused 0-0.9 μg/kg/h; adult Wistar rat; rat bacterial meningitis model), with or without rolipram (0-0.01 μg/kg/h), inhibits pleocytosis and reduces the lipopolysaccharide-induced increase in blood-brain barrier permeability (BBBP), indicative of decreased neutrophil-induced damage.

MRE-0470 | WRC 0470 | 2-(cyclohexylmethylidenehydrazino)adenos

Apoptosis

Adenosine Receptor

5-HT1A

——

——

144348-08-3

391.432

C17H25N7O4

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (319.35 mM)

Nc1nc(NN=CC2CCCCC2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years